TOL 3021

Drug Profile

TOL 3021

Alternative Names: BHT-3021; DNA plasmid vaccine for type 1 diabetes - Bayhill Therapeutics; RG 7426

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer Tolerion
  • Class Antihyperglycaemics; Diabetes mellitus vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Gene transference; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Jun 2013 Phase-II clinical trials in Type-1 diabetes mellitus in Australia (IM)
  • 27 Jun 2013 Phase-II clinical trials in Type-1 diabetes mellitus in New Zealand (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top